Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. - Wikidata - wikimedia - TriplyDB

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

http://www.wikidata.org/entity/Q43038398

about

The pharmacological management of osteoporosis Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective A review of denosumab for the treatment of osteoporosis New antiresorptive therapies for postmenopausal osteoporosis Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis Chronic kidney disease and osteoporosis: evaluation and management.In silico investigations of the anti-catabolic effects of pamidronate and denosumab on multiple myeloma-induced bone disease.Cellular mechanisms of bone remodeling Update on denosumab treatment in postmenopausal women with osteoporosis.Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis.Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis.Chronic kidney disease and the skeleton.Management of severe osteoporosis.Denosumab treatment for fibrous dysplasia.A review of the efficacy and safety of denosumab in postmenopausal women with osteoporosis.Medical treatment of osteoporotic vertebral fractures.Structure Model Index Does Not Measure Rods and Plates in Trabecular Bone.International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.Osteoporosis: now and the future Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis.Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee.Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.Histomorphometric interpretation of bone biopsies for the evaluation of osteoporosis treatment Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.Role of osteoclasts in regulating hematopoietic stem and progenitor cells.Eliminating the need for fasting with oral administration of bisphosphonates.(18)F-fluoride positron emission tomography measurements of regional bone formation in hemodialysis patients with suspected adynamic bone disease.The role of osteoblasts in bone metastasis.Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.Effects of denosumab treatment and discontinuation on human growth plates.Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Choosing a treatment for patients at the time a fracture is presented.Denosumab for the treatment of osteoporosis and cancer-related conditions.Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.Pharmacotherapy of Paget's disease of bone.The clinical use of denosumab for the management of low bone mineral density in postmenopausal women.

P2860

Q24605290-C2193593-D791-4F11-94CE-AFFEFC38303E Q26864207-B8EFE6F5-940A-45B9-A63E-03A2CAE08531 Q27005894-2BBDA371-E0AC-438F-9270-42C067E5FB39 Q27014775-5074AB15-F941-4EA6-9C7D-D4B2F9D96253 Q27026510-6F7A15EB-345F-474A-9ECE-BAEE8A32E1EF Q33570337-A0C28A0A-F3BF-48BF-A3E0-795A55580A85 Q33663460-E9F481D5-122E-4636-9E6B-56009ACD8775 Q33833414-EA89BE20-9888-4505-B3BC-D344660A5036 Q34427554-896014EB-35BF-4CA0-8F16-1344395E013A Q34525829-694B6781-F079-4A6C-8D1C-41D8F6C950B6 Q35260850-A6D7BB0C-5320-4BC3-875B-B60449EC3968 Q35589102-26EB2B8F-B4D6-4F14-89E7-8E4CE5E43A1C Q35689812-CA80A4E9-15FC-4CFA-8419-B70116B279AF Q35755179-0884FA27-BE1E-485C-8152-F1E4FF8940A6 Q35852252-EBB9107F-60FE-4A1F-86C8-19CD5AE05DD9 Q36040881-3D5FCE38-C136-4784-86F6-5C6000FDF21C Q36059455-76FA6339-6A7C-4B86-8D2C-AF3CADD58F54 Q36059589-DFA12F5B-1F2B-4F5D-90BF-60481006A188 Q36149699-6A6BCFB4-C349-4FA3-92EC-1245A344D48A Q36250826-A461E195-AEC3-4E94-B0ED-A0F01AA55494 Q36508374-4B419B5C-FFA3-44F3-98E5-B6607C0950A5 Q36564425-2CE6CA1C-AE36-4DBA-86F8-90152087E5FF Q36796273-CF21DBF4-A0E2-49A9-8F07-F69FABBB4297 Q36901599-EDF56FFC-2FE7-4CE1-95DC-298835D36D37 Q36935525-6F947E92-9927-49A4-8370-E8840D3E6270 Q37056290-AFC4EDEE-8879-49B6-848A-8E4CB74CD50B Q37192904-A6FF798C-4EC0-45BA-862A-B69524E14647 Q37199204-A187307E-21E6-43D4-9199-2FD734750BE4 Q37241261-7293C674-A401-4D78-B20B-E139D94AFB62 Q37245415-6F76A030-0B9A-4806-B268-88572DC14D9A Q37298652-F86C3F5F-E7FB-4121-B599-A125077D5208 Q37337490-25BC1249-EDD4-4279-8FE1-06103E3279F9 Q37421054-88AACDFA-A640-467F-A916-008391D09A98 Q37616880-4F0225B9-17C3-44E2-A673-1D3ADEE948F5 Q37661855-734640C2-FAE4-4625-BF1E-4A5CE883778A Q37886780-5CF926A2-1D6E-4AB6-B973-ED111B65FD8C Q37967111-F8C27667-C768-4EE7-BAF8-DE0E5F904DAD Q37982190-461E6C06-4FAC-4E41-849E-0F6E7AB6993A Q37984490-D04E8F49-C1D6-4708-9DB3-C5EFA520FB5E Q38006918-1496ACCF-0647-4A51-B509-F7D9BB282E88

P2860

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

http://www.wikidata.org/entity/Q43038398

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@en

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@nl

type

label

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@en

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@nl

prefLabel

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@en

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies.

@nl

P1433

Q43038398-C7983031-0234-45DE-8937-95B91387E8DB

P1476

Q43038398-FA099A13-9929-4D3E-B272-5437AD94A56E

P2093

Q43038398-05794301-5A71-419D-8CBC-635E2338A643

Q43038398-11EC8DDE-0265-493D-9A4F-7A1F66CB8FAD

Q43038398-1EF701A8-79B8-4FC2-8C47-DB2926C0F0B1

Q43038398-1FED6355-AA3B-48B3-BB18-762FAA9BB27B

Q43038398-2B782370-0D3D-48AF-BBE3-0A4C2474FD7E

Q43038398-3D2D6029-ADD8-43F3-8D2A-CCDEB0E140B0

Q43038398-410B978B-B783-4F2B-A99F-268F064C6C00

Q43038398-42FD4B1E-713B-4F53-95B6-9DF361B84A1E

Q43038398-7D1C98A3-D37A-42EA-B9BC-7E06222AB314

Q43038398-8583FE22-BA1E-4DB1-9CD0-A7F1E2D4146F

P2860

Q43038398-36E3DE59-9E0C-4E8E-931A-DACA9E336183

Q43038398-77D246EC-C125-478D-8FA5-D35B4C7F8A8D

P304

Q43038398-544F372D-0B01-4EDF-8308-03F57D06A1F1

P31

Q43038398-C0EE6954-4B43-4076-9EA5-6A5B62FF5B9F

P356

Q43038398-10F23824-E6F8-46FF-8129-F05DE76C4B1F

P433

Q43038398-B10B3B44-DE6D-45B1-9F19-F6EDF95B7870

P478

Q43038398-82196739-E9E1-4FD1-B7C7-870B5E21CB67

P50

Q43038398-AC6FA9B0-9038-457A-9175-9F51FEEA6DFC

Q43038398-F044B791-5BB7-426D-8FFF-F4CF935BBE20

P577

Q43038398-59297322-5B1C-4977-A566-FF3601EF48A2

P5875

Q43038398-9244F600-6CD9-4F45-B577-AC1F4C623F8C

P698

Q43038398-260FFDF3-067B-4DB3-8B93-5CE144FBF4EE

P356

P1433

Journal of Bone and Mineral Research

P1476

Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies

@en

P2093

Astrid Fahrleitner-Pammer

http://www.w3.org/2001/XMLSchema#string

Beiying Ding

http://www.w3.org/2001/XMLSchema#string

David W Dempster

http://www.w3.org/2001/XMLSchema#string

Denosumab Phase 3 Bone Histology Study Group

http://www.w3.org/2001/XMLSchema#string

Grattan Woodson

http://www.w3.org/2001/XMLSchema#string

Henry Bone

http://www.w3.org/2001/XMLSchema#string

Ivo Valter

http://www.w3.org/2001/XMLSchema#string

Jacques P Brown

http://www.w3.org/2001/XMLSchema#string

Javier San Martin

http://www.w3.org/2001/XMLSchema#string

Katre Maasalu

http://www.w3.org/2001/XMLSchema#string

P2860

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

P304

2256-2265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JBMR.149

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44659162

http://www.w3.org/2001/XMLSchema#string

P698

20533525

http://www.w3.org/2001/XMLSchema#string